Shots: The companies sign a purchase agreement with Covax to supply 40M doses of the COVID-19 vaccine. First deliveries are expected in Q1’ 2021, subject to the execution of supply agreements under the Covax Facility structure Covax includes an Advanced Market Commitment (AMC) financial mechanism under which Pfizer and BioNTech will provide access COVID-19 vaccines […]Read More
Shots: The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively Results: @12wks. clinical remission as per CDAI (45%/42% […]Read More
Shots: In terms of the agreement, lilly will commercialize the system, which is currently in development & will include an insulin pump developed & manufactured by ypsomed Ypsomed’s insulin pump has been marketed in europe since 2016, available in 21 countries as the mylife ypsopump. Lilly will commercialize a version of this insulin pump, along […]Read More
Shots: Microsoft enters collaboration with Illumina, Twist, and Western Digital to establish a roadmap for the industry towards the wider use of DNA data storage. These companies are the founding members of the alliance Ten additional technology leaders join founding members to together advance industry roadmap, set the stage for widespread adoption of new long-term […]Read More
Shots: The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of […]Read More
Shots: The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to […]Read More
Shots: The two companies collaborated to jointly conduct P-II study combining BNT111 FixVac and Libtayo in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma with the expected initiation of the study in Q4’20 The companies will equally share the development costs for the clinical trial and will contribute their products for the trial. […]Read More
Shots: The companies expanded the collaboration to support the needs of patients with kidney disease via digital health solutions. The agreement integrates Ayogo’s LifePlan digital platform with Baxter’s expertise in renal care to develop mobile apps and digital solutions that bring personalized and timely support to patients with kidney failure Baxter made an equity investment […]Read More
Shots: Kymera to receive $150M up front, $2B as development, regulatory and commercial milestones along with royalties on sales of therapies. Additionally, the company has an option to develop and commercialize the two programs in the US while retaining global rights to its IRAK4 program in oncology indications. Sanofi will get a global right to […]Read More
Shots: Reverie Labs to receive up front and is eligible to receive pre/clinical, regulatory milestones, as well as royalties on Roche’s sales of drug candidates, emerges from the collaboration Reverie Labs will deploy its technology platform to perform virtual screening, hit-to-lead generation, and lead optimization on kinase inhibitor discovery programs, alongside scientists at Roche and […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
